Teva Pharmaceutical Industries (NYSE:TEVA) Research Coverage Started at Leerink Partners

Leerink Partners started coverage on shares of Teva Pharmaceutical Industries (NYSE:TEVA) in a report released on Wednesday, MarketBeat reports. The brokerage issued an outperform rating and a $45.00 price objective on the stock.

Several other equities research analysts have also recently weighed in on the company. Piper Sandler upped their target price on Teva Pharmaceutical Industries from $42.00 to $44.00 and gave the stock an “overweight” rating in a research note on Tuesday, July 28th. Wall Street Zen lowered Teva Pharmaceutical Industries from a “buy” rating to a “hold” rating in a research note on Sunday, July 12th. UBS Group boosted their price target on Teva Pharmaceutical Industries from $42.00 to $48.00 and gave the stock a “buy” rating in a report on Friday, September 4th. Weiss Ratings raised Teva Pharmaceutical Industries from a “hold (c-)” rating to a “hold (c)” rating in a report on Friday, August 21st. Finally, Barclays upped their price objective on Teva Pharmaceutical Industries from $40.00 to $42.00 and gave the stock an “overweight” rating in a research report on Wednesday, August 12th. Ten equities research analysts have rated the stock with a Buy rating and one has assigned a Hold rating to the company. According to MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average target price of $43.10.

Teva Pharmaceutical Industries Trading Up 1.8%

Shares of Teva Pharmaceutical Industries stock opened at $37.01 on Wednesday. The company has a quick ratio of 0.67, a current ratio of 0.88 and a debt-to-equity ratio of 1.56. Teva Pharmaceutical Industries has a 12-month low of $18.21 and a 12-month high of $38.37. The company has a market capitalization of $43.13 billion, a price-to-earnings ratio of 61.68, a PEG ratio of 4.53 and a beta of 0.87. The firm’s 50-day moving average price is $34.91 and its two-hundred day moving average price is $33.37.

Teva Pharmaceutical Industries (NYSE:TEVA) last issued its earnings results on Tuesday, June 30th. The company reported $0.02 EPS for the quarter. The company had revenue of $4.14 billion during the quarter. Teva Pharmaceutical Industries had a net margin of 4.08% and a return on equity of 32.64%. On average, analysts forecast that Teva Pharmaceutical Industries will post 1.94 earnings per share for the current fiscal year.

Institutional Trading of Teva Pharmaceutical Industries

A number of hedge funds have recently added to or reduced their stakes in TEVA. Aster Capital Management DIFC Ltd acquired a new position in shares of Teva Pharmaceutical Industries during the fourth quarter worth $25,000. Cornerstone Planning Group LLC boosted its holdings in shares of Teva Pharmaceutical Industries by 547.1% during the 1st quarter. Cornerstone Planning Group LLC now owns 893 shares of the company’s stock valued at $27,000 after acquiring an additional 755 shares in the last quarter. Allworth Financial LP boosted its holdings in shares of Teva Pharmaceutical Industries by 53.8% during the 4th quarter. Allworth Financial LP now owns 941 shares of the company’s stock valued at $29,000 after acquiring an additional 329 shares in the last quarter. EverSource Wealth Advisors LLC grew its position in Teva Pharmaceutical Industries by 51.8% during the 4th quarter. EverSource Wealth Advisors LLC now owns 1,011 shares of the company’s stock worth $32,000 after acquiring an additional 345 shares during the last quarter. Finally, Global Retirement Partners LLC grew its position in Teva Pharmaceutical Industries by 27.3% during the 4th quarter. Global Retirement Partners LLC now owns 1,360 shares of the company’s stock worth $42,000 after acquiring an additional 292 shares during the last quarter. Institutional investors and hedge funds own 54.05% of the company’s stock.

About Teva Pharmaceutical Industries

Teva Pharmaceutical Industries Ltd. is a global pharmaceutical company headquartered in Tel Aviv, Israel. The company develops, manufactures and markets generic medicines, innovative specialty medicines, biosimilars, over-the-counter products and active pharmaceutical ingredients. Its portfolio serves a broad range of therapeutic areas, including central nervous system disorders, respiratory conditions, migraine, oncology and movement disorders.

Teva’s specialty medicines include treatments for conditions such as multiple sclerosis, migraine and tardive dyskinesia, while its generic medicines business supplies products across numerous therapeutic categories and dosage forms.